

09/865950

d his

(FILE 'CAPLUS' ENTERED AT 16:46:48 ON 01 JUL 2003)
DELETE HIS
E WO 200190106/PN
L1 1 S E3
SELECT L1 1 RN
L2 1252 S E1-E31
S L2 AND C18 H23 F2 N O3/MF

FILE 'REGISTRY' ENTERED AT 16:55:25 ON 01 JUL 2003
L3 20 S C18 H23 F2 N O3/MF

FILE 'CAPLUS' ENTERED AT 16:55:25 ON 01 JUL 2003
L4 12 S L3
L5 2 S L2 AND L4

FILE 'REGISTRY' ENTERED AT 16:56:30 ON 01 JUL 2003
L6 31 S L2
L7 1 S L6 AND C16 H19 F2 N O2/MF
L8 1 S L7
L9 1 S L6 AND C18 H23 F2 N O3/MF

=>


09/865950

=> s 16 and C16 H19 F2 N O2/mf
14 C16 H19 F2 N O2/MF
L7 1 L6 AND C16 H19 F2 N O2/MF

=> d scan

L7 1 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Cyclohexanecarboxamide, 4,4-difluoro-N-[(1S)-3-oxo-1-phenylpropyl]- (9CI)
MF C16 H19 F2 N O2

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> s 17
14 C16 H19 F2 N O2/MF
L8 1 L6 AND C16 H19 F2 N O2/MF


=> d all

L8 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2003 ACS
RN 376348-78-6 REGISTRY
CN Cyclohexanecarboxamide, 4,4-difluoro-N-[(1S)-3-oxo-1-phenylpropyl]- (9CI)
(CA INDEX NAME)
FS STEREOSEARCH
MF C16 H19 F2 N O2
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Ring System Data

Elemental Analysis	Elemental Sequence	Size of the Rings	Ring System Formula	Ring Identifier	RID Occurrence Count
EA	ES	SZ	RF	RID	Count
C6	C6	6	C6	46.150.1	1
C6	C6	6	C6	46.150.18	1

Absolute stereochemistry.



Calculated Properties (CALC)

PROPERTY (CODE)	VALUE	CONDITION	NOTE
Bioconc. Factor (BCF)	16.0	pH 1	(1) ACD
Bioconc. Factor (BCF)	16.1	pH 4	(1) ACD
Bioconc. Factor (BCF)	16.1	pH 7	(1) ACD
Bioconc. Factor (BCF)	16.1	pH 8	(1) ACD

09/865950

Bioconc. Factor (BCF)	16.1	pH 10	(1) ACD
Boiling Point (BP)	461.4 +/- 40.0 deg C	760.0 Torr	(1) ACD
Enthalpy of Vap. (HVAP)	72.23 +/- 3.0 kJ/mol		(1) ACD
Flash Point (FP)	232.9 +/- 49.2 deg C		(1) ACD
Freely Rotatable Bonds (FRB)	6		(1) ACD
H acceptors (HAC)	3		(1) ACD
H donors (HD)	1		(1) ACD
Koc (KOC)	253	pH 1	(1) ACD
Koc (KOC)	254	pH 4	(1) ACD
Koc (KOC)	254	pH 7	(1) ACD
Koc (KOC)	254	pH 8	(1) ACD
Koc (KOC)	254	pH 10	(1) ACD
logD (LOGD)	1.89	pH 1	(1) ACD
logD (LOGD)	1.89	pH 4	(1) ACD
logD (LOGD)	1.89	pH 7	(1) ACD
logD (LOGD)	1.89	pH 8	(1) ACD
logD (LOGD)	1.89	pH 10	(1) ACD
logP (LOGP)	1.891 +/- 0.582		(1) ACD
Molar Solubility (SLB.MOL)	<0.01 mol/L	pH 1	(1) ACD
Molar Solubility (SLB.MOL)	<0.01 mol/L	pH 4	(1) ACD
Molar Solubility (SLB.MOL)	<0.01 mol/L	pH 7	(1) ACD
Molar Solubility (SLB.MOL)	<0.01 mol/L	pH 8	(1) ACD
Molar Solubility (SLB.MOL)	<0.01 mol/L	pH 10	(1) ACD
Molecular Weight (MW)	295.32		(1) ACD
Vapor Pressure (VP)	1.07E-08 Torr	25.0 deg C	(1) ACD

(1) Calculated using Advanced Chemistry Development (ACD) Software Solaris
V4.76 ((C) 1994-2003 ACD)

1 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES IN FILE CAPLUS (1957 TO DATE)


REFERENCE 1

AN 136:6195 CA
TI Preparation of therapeutic tropane derivatives
IN Perros, Manoussos; Price, David Anthony; Stammen, Blanda Luzia Christa;
Wood, Anthony
PA Pfizer Limited, UK; Pfizer Inc.
SO PCT Int. Appl., 79 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM C07D451-00
CC 31-3 (Alkaloids)
Section cross-reference(s): 1, 63

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001090106	A2	20011129	WO 2001-IB806	20010509
	WO 2001090106	A3	20020328		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	EP 1284974	A2	20030226	EP 2001-925808	20010509
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
	BR 2001010955	A	20030603	BR 2001-10955	20010509
	US 2002013337	A1	20020131	US 2001-865950	20010525
	NO 2002005227	A	20021031	NO 2002-5227	20021031
PRAI	GB 2000-14046	20000526			
	GB 2000-15835	20000627			
	US 2000-214587P	20000627			
	US 2000-219202P	20000719			
	WO 2001-IB806	20010509			

GI



AB The tropanes I (R1 = C3-6 cycloalkyl optionally substituted by one or more fluorine atoms, C1-6 alkyl optionally substituted by one or more fluorine atoms, C3-6 cycloalkylmethyl optionally ring-substituted by one or more fluorine atoms; R2 = Ph optionally substituted by one or more fluorine atoms) and their pharmaceutically acceptable salts and solvates were prep'd. Thus, (1S)-3-[3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-exo-8-azabicyclo[3.2.1]oct-8-yl]-1-phenyl-1-propanamine, prepn. given, was treated with cyclobutanecarboxylic acid in presence of polymer bound N-benzyl-N'-cyclohexylcarbodiimide to give I (R1 = cyclobutyl, R2 = Ph). I had an IC₅₀ value of less than 10nM in the assay for CCR5 binding.
ST tropane deriv prep'n CCR5 receptor
IT Chemokine receptors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (CCR5; prep'n. of tropane derivs. as CCR5 receptor antagonists)
IT Intestine, disease
 (inflammatory; prep'n. of tropane derivs. as CCR5 receptor antagonists)
IT Anti-AIDS agents
 Anti-inflammatory agents
 Crystal structure
 Molecular structure
 Respiratory distress syndrome
 Respiratory tract, disease
 (prep'n. of tropane derivs. as CCR5 receptor antagonists)
IT Chemokines
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (prep'n. of tropane derivs. as CCR5 receptor antagonists)
IT 376348-65-1P
 RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prep'n. of tropane derivs. as CCR5 receptor antagonists)
IT 376348-62-8P 376348-63-9P 376348-64-0P 376348-66-2P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prep'n. of tropane derivs. as CCR5 receptor antagonists)
IT 696-59-3, 2,5-Dimethoxytetrahydrofuran 3082-69-7 3287-99-8,
 Benzylamine hydrochloride 120686-18-2 122665-97-8 376348-71-9
 376348-74-2
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (prep'n. of tropane derivs. as CCR5 receptor antagonists)
IT 28957-72-4P 37088-66-7P 76272-34-9P 76272-36-1P 135865-78-0P
 190189-97-0P 376348-67-3P 376348-68-4P 376348-69-5P 376348-70-8P
 376348-72-0P 376348-73-1P 376348-75-3P 376348-76-4P 376348-77-5P
 376348-78-6P 376348-79-7P 376348-80-0P 376348-81-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (prep'n. of tropane derivs. as CCR5 receptor antagonists)


=> s 16 and C18 H23 F2 N O3/mf
 20 C18 H23 F2 N O3/MF
L9 1 L6 AND C18 H23 F2 N O3/MF

=> d scan

L9 1 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Benzenepropanoic acid, .beta.-[(4,4-difluorocyclohexyl)carbonyl]amino]-, ethyl ester, (.beta.-S)- (9CI)
MF C18 H23 F2 N O3

Absolute stereochemistry.

09/865950



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED


=> d all

L9 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2003 ACS
RN 376348-76-4 REGISTRY
CN Benzenepropanoic acid, .beta.-[[[(4,4-difluorocyclohexyl)carbonyl]amino]-, ethyl ester, (.beta.S)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C18 H23 F2 N O3
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Ring System Data

Elemental Analysis	Elemental Sequence	Size of the Rings	Ring System Formula	Ring Identifier RID	RID Occurrence Count
EA	ES	SZ	RF	RID	Count
C6	C6	6	C6	46.150.1	1
C6	C6	6	C6	46.150.18	1

Absolute stereochemistry.



Calculated Properties (CALC)

PROPERTY (CODE)	VALUE	CONDITION	NOTE
Bioconc. Factor (BCF)	59.9	pH 1	(1) ACD
Bioconc. Factor (BCF)	60.3	pH 4	(1) ACD
Bioconc. Factor (BCF)	60.3	pH 7	(1) ACD
Bioconc. Factor (BCF)	60.3	pH 8	(1) ACD
Bioconc. Factor (BCF)	60.3	pH 10	(1) ACD
Boiling Point (BP)	500.8 +/- 50.0 deg C	760.0 Torr	(1) ACD
Enthalpy of Vap. (HVAP)	76.95 +/- 3.0 kJ/mol		(1) ACD
Flash Point (FP)	256.7 +/- 54.2 deg C		(1) ACD
Freely Rotatable Bonds (FRB)	8		(1) ACD
H acceptors (HAC)	4		(1) ACD
H donors (HD)	1		(1) ACD
Koc (KOC)	650	pH 1	(1) ACD
Koc (KOC)	654	pH 4	(1) ACD
Koc (KOC)	654	pH 7	(1) ACD
Koc (KOC)	654	pH 8	(1) ACD
Koc (KOC)	654	pH 10	(1) ACD
logD (LOGD)	2.64	pH 1	(1) ACD
logD (LOGD)	2.64	pH 4	(1) ACD
logD (LOGD)	2.64	pH 7	(1) ACD
logD (LOGD)	2.64	pH 8	(1) ACD

logD (LOGD)	2.64	pH 10	(1) ACD
logP (LOGP)	2.645+/-0.570	pH 1	(1) ACD
Molar Solubility (SLB.MOL)	<0.01 mol/L	pH 4	(1) ACD
Molar Solubility (SLB.MOL)	<0.01 mol/L	pH 7	(1) ACD
Molar Solubility (SLB.MOL)	<0.01 mol/L	pH 8	(1) ACD
Molar Solubility (SLB.MOL)	<0.01 mol/L	pH 10	(1) ACD
Molecular Weight (MW)	339.38		(1) ACD
Vapor Pressure (VP)	3.68E-10 Torr	25.0 deg C	(1) ACD

(1) Calculated using Advanced Chemistry Development (ACD) Software Solaris V4.76 ((C) 1994-2003 ACD)

1 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1


AN 136:6195 CA
 TI Preparation of therapeutic tropane derivatives
 IN Perros, Manoussos; Price, David Anthony; Stammen, Blanda Luzia Christa;
 Wood, Anthony
 PA Pfizer Limited, UK; Pfizer Inc.
 SO PCT Int. Appl., 79 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM C07D451-00
 CC 31-3 (Alkaloids)
 Section cross-reference(s): 1, 63

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001090106	A2	20011129	WO 2001-IB806	20010509
WO 2001090106	A3	20020328		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1284974	A2	20030226	EP 2001-925808	20010509
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001010955	A	20030603	BR 2001-10955	20010509
US 2002013337	A1	20020131	US 2001-865950	20010525
NO 2002005227	A	20021031	NO 2002-5227	20021031

PRAI GB 2000-14046 20000526
 GB 2000-15835 20000627
 US 2000-214587P 20000627
 US 2000-219202P 20000719
 WO 2001-IB806 20010509

GI



AB The tropanes I (R1 = C3-6 cycloalkyl optionally substituted by one or more fluorine atoms, C1-6 alkyl optionally substituted by one or more fluorine atoms, C3-6 cycloalkylmethyl optionally ring-substituted by one or more fluorine atoms; R2 = Ph optionally substituted by one or more fluorine atoms) and their pharmaceutically acceptable salts and solvates were prepd. Thus, (1S)-3-[3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-exo-8-azabicyclo[3.2.1]oct-8-yl]-1-phenyl-1-propanamine, prepn. given, was treated with cyclobutanecarboxylic acid in presence of polymer bound N-benzyl-N'-cyclohexylcarbodiimide to give I (R1 = cyclobutyl, R2 = Ph). I had an IC50 value of less than 10nM in the assay for CCR5 binding.

09/865950

ST tropane deriv prepn CCR5 receptor
IT Chemokine receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CCR5; prepn. of tropane derivs. as CCR5 receptor antagonists)
IT Intestine, disease
(inflammatory; prepn. of tropane derivs. as CCR5 receptor antagonists)
IT Anti-AIDS agents
Anti-inflammatory agents
Crystal structure
Molecular structure
Respiratory distress syndrome
Respiratory tract, disease
(prepn. of tropane derivs. as CCR5 receptor antagonists)
IT Chemokines
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(prepn. of tropane derivs. as CCR5 receptor antagonists)
IT 376348-65-1P
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of tropane derivs. as CCR5 receptor antagonists)
IT 376348-62-8P 376348-63-9P 376348-64-0P 376348-66-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of tropane derivs. as CCR5 receptor antagonists)
IT 696-59-3, 2,5-Dimethoxytetrahydrofuran 3082-69-7 3287-99-8,
Benzylamine hydrochloride 120686-18-2 122665-97-8 376348-71-9
376348-74-2
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of tropane derivs. as CCR5 receptor antagonists)
IT 28957-72-4P 37088-66-7P 76272-34-9P 76272-36-1P 135865-78-0P
190189-97-0P 376348-67-3P 376348-68-4P 376348-69-5P 376348-70-8P
376348-72-0P 376348-73-1P 376348-75-3P 376348-76-4P 376348-77-5P
376348-78-6P 376348-79-7P 376348-80-0P 376348-81-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of tropane derivs. as CCR5 receptor antagonists)

09/865950

=> d his

(FILE 'CPLUS' ENTERED AT 16:46:48 ON 01 JUL 2003)
DELETE HIS
E WO 200190106/PN

L1 1 S E3
SELECT L1 1 RN
L2 1252 S E1-E31
S L2 AND C18 H23 F2 N O3/MF

FILE 'REGISTRY' ENTERED AT 16:55:25 ON 01 JUL 2003
L3 20 S C18 H23 F2 N O3/MF

FILE 'CPLUS' ENTERED AT 16:55:25 ON 01 JUL 2003
L4 12 S L3
L5 2 S L2 AND L4


FILE 'REGISTRY' ENTERED AT 16:56:30 ON 01 JUL 2003
L6 31 S L2
L7 1 S L6 AND C16 H19 F2 N O2/MF
L8 1 S L7
L9 1 S L6 AND C18 H23 F2 N O3/MF

=> s 19
20 C18 H23 F2 N O3/MF
L10 1 L6 AND C18 H23 F2 N O3/MF

=> d

L10 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2003 ACS
RN 376348-76-4 REGISTRY
CN Benzenepropanoic acid, .beta.-{[(4,4-difluorocyclohexyl)carbonyl]amino}-,
ethyl ester, (.beta.S)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C18 H23 F2 N O3
SR CA
LC STN Files: CA, CPLUS, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES IN FILE CPLUS (1957 TO DATE)